rivastigmine has been researched along with curcumin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 9 (40.91) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, SX; Sun, ZQ; Tu, LX; Zhuo, FJ | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Maqbool, M; Meena, P; Mobashir, M; Shandilya, A; Singh, A; Tiwari, M | 1 |
| Chen, H; Shang, J; Sun, X; Tan, W; Tian, Y; Wang, H; Wang, L; Wang, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Chen, Q; Digiacomo, M; Nesi, G; Pi, R; Rapposelli, S; Sestito, S; Wang, S; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Feng, F; He, S; Jiang, H; Jiang, X; Liu, W; Qu, W; Sun, H; Zhou, J | 1 |
| Huang, W; Li, Q; Liang, M; Shen, Z; Tang, L; Wang, B; Wang, Q; Zhang, C; Zhang, Z; Zheng, X | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Chen, YP; Guo, HY; Luo, W; Lv, JW; Ma, J; Song, ZY; Wang, CJ; Wang, T; Zhang, ZY | 1 |
| Cheng, X; Liu, W; Ma, Q; Sang, Z; Shi, J; Tan, Z; Wang, K; Wei, R; Yu, L; Zhao, Y; Zhu, G | 1 |
| Cheng, X; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Bai, P; Chen, Z; Lan, Y; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, C; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Cao, Z; Cong, S; Deng, Y; Liu, Z; Song, Q; Tan, Z; Yu, G | 1 |
| Chowdhury, SR; Fu, L; Gu, J; Hu, Y; Jiang, F; Lam, C; Lei, S; Lu, D; Tavallaie, MS; Wang, J | 1 |
| Deng, Y; Liu, X; Liu, Z; Shi, Y; Song, Q; Tan, Z; Yu, G; Zhang, H; Zhong, F | 1 |
| He, Y; Liu, W; Mi, J; Sang, Z; Wu, A; Yang, J; Zhou, Y; Zhu, G | 1 |
| Banerjee, BD; Jain, S; Khurana, S; Mediratta, PK; Sharma, KK | 1 |
| Hu, Y; Li, Y; Peng, P; Sheng, R; Tang, L | 1 |
| Bhanuprakash, K; Chitumalla, RK; Karthikraj, R; Nagaveni, V; Prabhakar, S; Vairamani, M | 1 |
1 review(s) available for rivastigmine and curcumin
| Article | Year |
|---|---|
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.
Topics: Animals; Drug Combinations; Drug Delivery Systems; Drug Design; Humans; Ligands | 2019 |
21 other study(ies) available for rivastigmine and curcumin
| Article | Year |
|---|---|
Design and discovery of Novel Thiazole acetamide derivatives as anticholinesterase agent for possible role in the management of Alzheimer's.
Topics: Acetamides; Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Binding Sites; Butyrylcholinesterase; Cell Survival; Cholinesterase Inhibitors; Drug Design; Drug Evaluation, Preclinical; HeLa Cells; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Structure-Activity Relationship; Thiazoles | 2016 |
Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Humans; Molecular Structure; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Stilbenes; Structure-Activity Relationship | 2016 |
Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Humans; Kinetics; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Conformation; Pyrimidines | 2016 |
Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Catalytic Domain; Cell Line, Tumor; Chalcones; Cholinesterase Inhibitors; Humans; Hydrogen Bonding; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxidative Stress; Reactive Oxygen Species; Rivastigmine; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biological Products; Butyrylcholinesterase; Cell Death; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Free Radical Scavengers; Glutamic Acid; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rivastigmine; Structure-Activity Relationship | 2017 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Development of the "hidden" multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Chelating Agents; Cholinesterase Inhibitors; Drug Design; ERG1 Potassium Channel; Male; Mice; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Nootropic Agents; Peptide Fragments; Protein Multimerization; Quinolines; Rats, Sprague-Dawley; Structure-Activity Relationship; Zebrafish | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
Synthesis, in vitro and in vivo biological evaluation of novel graveolinine derivatives as potential anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Butyrylcholinesterase; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Hep G2 Cells; Horses; Humans; Male; Methoxsalen; Mice; Molecular Structure; PC12 Cells; Peptide Fragments; Rats; Structure-Activity Relationship | 2020 |
Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apigenin; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Ligands; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Rats; Rivastigmine; Structure-Activity Relationship; Zebrafish | 2020 |
The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Development; Humans; Ligands; Molecular Structure; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Structure-Activity Relationship; Zebrafish | 2020 |
Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Mice; Mice, Inbred Strains; Microsomes, Liver; Molecular Structure; Peptide Fragments; Positron Emission Tomography Computed Tomography; Protein Aggregates; Rats; Structure-Activity Relationship; Zebrafish | 2020 |
Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Benzylidene Compounds; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Electrophorus; Female; Humans; Male; Mannich Bases; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2021 |
Synthesis, biological evaluation and molecular modeling of benzofuran piperidine derivatives as Aβ antiaggregant.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzofurans; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Piperidines; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship | 2021 |
Development of novel 2-aminoalkyl-6-(2-hydroxyphenyl)pyridazin-3(2H)-one derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cholinesterase Inhibitors; Drug Design; Mice; Protein Aggregates; Structure-Activity Relationship | 2022 |
Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Drug Development; Flavanones; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2022 |
Protective role of curcumin on colchicine-induced cognitive dysfunction and oxidative stress in rats.
Topics: Acetylcholinesterase; Animals; Antioxidants; Brain; Catalase; Cholinesterase Inhibitors; Cognition Disorders; Colchicine; Curcumin; Glutathione; Lipid Peroxidation; Male; Malondialdehyde; Memory; Neuroprotective Agents; Oxidative Stress; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine | 2012 |
Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Curcumin; Dose-Response Relationship, Drug; Drug Design; Ligands; Molecular Docking Simulation; Molecular Structure; Phenylcarbamates; Rivastigmine; Structure-Activity Relationship | 2014 |
Gas-phase basicity and proton affinity measurements of Alzheimer's disease drugs by the extended kinetic method and a theoretical investigation.
Topics: Alzheimer Disease; Curcumin; Galantamine; Humans; Neuroprotective Agents; Protons; Rivastigmine; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2020 |